Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.
Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.
Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.
View all videosASH 2020
HORIZON subgroup analyses: #Melfufen and dexamethasone in R/R #Myeloma w/ @mvmateos of @usal: http://ow.ly/AGxL50D4XEk
@VJHemOnc @ASH_hematology #ASH20 #HemOnc #MMsm #MultipleMyeloma
The consolidation/maintenance principles were first adapted by Bart Barlogie’s Total Therapy approach (circa 1989) that all of us have adapted in modern schema, including RVD maintenance (circa 2005-2006) well before anyone else, we have to credit him first 😊. #mmsm https://twitter.com/sagarlonialmd/status/1350444686981423104
This is the principle behind our RVD consolidation and maintenance for high risk from 2013 (Nooka et al, leukemia). What we don’t know is if changing therapy for mrd positive patients changes outcomes. We also don’t know if stopping is a good idea and when. https://twitter.com/mohty_ebmt/status/1350439578365272064
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma - concept we follow and now aim for sustained MRD-ve in #mmsm @Mohty_EBMT @SagarLonialMD https://pubmed.ncbi.nlm.nih.gov/18470907/
The role of MRD is increasingly well established in myeloma. We have to move forward with the MRD-guided therapy prospective protocols. @BloodJournal @BrunoPaiva_UNAV @mvmateos
4ASH 2020
Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.
Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.
Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.
View all videosHORIZON subgroup analyses: #Melfufen and dexamethasone in R/R #Myeloma w/ @mvmateos of @usal: http://ow.ly/AGxL50D4XEk
@VJHemOnc @ASH_hematology #ASH20 #HemOnc #MMsm #MultipleMyeloma
The consolidation/maintenance principles were first adapted by Bart Barlogie’s Total Therapy approach (circa 1989) that all of us have adapted in modern schema, including RVD maintenance (circa 2005-2006) well before anyone else, we have to credit him first 😊. #mmsm https://twitter.com/sagarlonialmd/status/1350444686981423104
This is the principle behind our RVD consolidation and maintenance for high risk from 2013 (Nooka et al, leukemia). What we don’t know is if changing therapy for mrd positive patients changes outcomes. We also don’t know if stopping is a good idea and when. https://twitter.com/mohty_ebmt/status/1350439578365272064
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma - concept we follow and now aim for sustained MRD-ve in #mmsm @Mohty_EBMT @SagarLonialMD https://pubmed.ncbi.nlm.nih.gov/18470907/
The role of MRD is increasingly well established in myeloma. We have to move forward with the MRD-guided therapy prospective protocols. @BloodJournal @BrunoPaiva_UNAV @mvmateos
4
